Updated: Injectable form of argenx drug Vyvgart fails PhIII study in autoimmune platelet disease
A Dutch biotech company that’s posted win after win in clinical studies of its autoimmune disease drug disclosed its first major failure of the medicine …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.